Pharmacological characterization of vasopressin aggregation response of human platelets
- 1 November 1985
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 40 (3) , 425-432
- https://doi.org/10.1016/0049-3848(85)90278-6
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Vasopressin inhibits the adenylate cyclase activity of human platelet particulate fraction through V1‐receptorsFEBS Letters, 1983
- Some properties of the human platelet vasopressin receptorThrombosis Research, 1983
- Design of more potent and selective antagonists of the antidiuretic responses to arginine-vasopressin devoid of antidiuretic agonismJournal of Medicinal Chemistry, 1982
- Is the Pro-Adhesive Activity of Plasma Von Willebrand Factor Counteracted by a Physiological Inhibitor of Platelet Adhesiveness?Clinical Science, 1982
- Human platelet vasopressin receptorsLife Sciences, 1982
- Design of more potent antagonists of the antidiuretic responses to arginine-vasopressinJournal of Medicinal Chemistry, 1982
- Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressinJournal of Medicinal Chemistry, 1981
- [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine]arginine-vasopressin and [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)]arginine-vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressinJournal of Medicinal Chemistry, 1980
- Aggregation of human blood platelets by vasopressinAmerican Journal of Physiology-Legacy Content, 1972